Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Mar;3(1):29-38.
doi: 10.1093/nop/npv016. Epub 2015 Jul 1.

Survival trends of grade I, II, and III astrocytoma patients and associated clinical practice patterns between 1999 and 2010: A SEER-based analysis

Xuezhi Dong  1 , Abraham Noorbakhsh  1 , Brian R Hirshman  1 , Tianzan Zhou  1 , Jessica A Tang  1 , David C Chang  1 , Bob S Carter  1 , Clark C Chen  1
Affiliations

Survival trends of grade I, II, and III astrocytoma patients and associated clinical practice patterns between 1999 and 2010: A SEER-based analysis

Xuezhi Dong et al. Neurooncol Pract. 2016 Mar.

Abstract

Background: The survival trends and the patterns of clinical practice pertaining to radiation therapy and surgical resection for WHO grade I, II, and III astrocytoma patients remain poorly characterized.

Methods: Using the Surveillance, Epidemiology and End Results (SEER) database, we identified 2497 grade I, 4113 grade II, and 2755 grade III astrocytomas during the period of 1999-2010. Time-trend analyses were performed for overall survival, radiation treatment (RT), and the extent of surgical resection (EOR).

Results: While overall survival of grade I astrocytoma patients remained unchanged during the study period, we observed improved overall survival for grade II and III astrocytoma patients (Tarone-Ware P < .05). The median survival increased from 44 to 57 months and from 15 to 24 months for grade II and III astrocytoma patients, respectively. The differences in survival remained significant after adjusting for pertinent variables including age, ethnicity, marital status, sex, tumor size, tumor location, EOR, and RT status. The pattern of clinical practice in terms of EOR for grade II and III astrocytoma patients did not change significantly during this study period. However, there was decreased RT utilization as treatment for grade II astrocytoma patients after 2005.

Conclusion: Results from the SEER database indicate that there were improvements in the overall survival of grade II and III astrocytoma patients over the past decade. Analysis of the clinical practice patterns identified potential opportunities for impacting the clinical course of these patients.

Keywords: WHO grade I, II, III astrocytomas; population-based SEER database; practice pattern; survival.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
(A) Kaplan-Meier plots of 10-year survival by time period for patients with WHO grade I-IV astrocytomas. Note the survival rate (y-axis) ranges from 0.85 to 1 for grade I pilocytic astrocytoma, from 0.25 to 1 for grade II diffuse astrocytoma, and from 0 to 1 for grade III anaplastic astrocytoma and grade IV glioblastoma. (B) Kaplan-Meier plots of 2-year survival by time period for patients with WHO grade I-IV astrocytomas. Note the survival rate (y-axis) ranges from 0.9 to 1 for grade I pilocytic astrocytoma, from 0.5 to 1 for grade II diffuse astrocytoma, from 0.25 to 1 for grade III anaplastic astrocytoma, and from 0 to 1 for grade IV glioblastoma.
Fig. 1.
Fig. 1.
(A) Kaplan-Meier plots of 10-year survival by time period for patients with WHO grade I-IV astrocytomas. Note the survival rate (y-axis) ranges from 0.85 to 1 for grade I pilocytic astrocytoma, from 0.25 to 1 for grade II diffuse astrocytoma, and from 0 to 1 for grade III anaplastic astrocytoma and grade IV glioblastoma. (B) Kaplan-Meier plots of 2-year survival by time period for patients with WHO grade I-IV astrocytomas. Note the survival rate (y-axis) ranges from 0.9 to 1 for grade I pilocytic astrocytoma, from 0.5 to 1 for grade II diffuse astrocytoma, from 0.25 to 1 for grade III anaplastic astrocytoma, and from 0 to 1 for grade IV glioblastoma.
See this image and copyright information in PMC

References

    1. Dolecek TA, Propp JM, Stroup NE et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro Oncol. 2012;14:Suppl 5:v1–49. - PMC - PubMed
    1. Bartek J Jr., Ng K, Bartek J et al. Key concepts in glioblastoma therapy. J Neurol Neurosurg Psychiatry. 2012;83(7):753–760. - PubMed
    1. Ng K, Kim R, Kesari S et al. Genomic profiling of glioblastoma: convergence of fundamental biologic tenets and novel insights. J Neurooncol. 2012;107(1):1–12. - PubMed
    1. Louis DN, Ohgaki H, Wiestler OD et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97–109. - PMC - PubMed
    1. Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol. 2005;109(1):93–108. - PubMed